SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
March 14, 2000
(Date of Report)
March 9, 2000
(Date of earliest event reported)
GERON CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-20859 75-2287752
(State of Incorporation) (Commission File No.) (IRS Employer
Identification No.)
230 Constitution Drive
Menlo Park, California 94025
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (650) 473-7700
Item 5. Other Events
We are filing this Current Report on Form 8-K to make generally
available certain information regarding the Registrant. A copy of the
Registrant's press release announcing the sale of common stock and warrants
is set forth in Exhibit 99.1 to this Current Report on Form 8-K and is
hereby incorporated by reference herein.
Item 7 Financial Statements, Pro Forma Financial Information and
Exhibits
(c) Exhibits
99.1 Press Release issued by the Registrant on March 10, 2000.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunder duly authorized.
GERON CORPORATION
(Registrant)
Date: March 14, 2000 By: /s/ David L. Greenwood
------------------------------
Name: David L. Greenwood
Title: Senior Vice President and
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Title
99.1 Press Release issued by the Registrant on March 10, 2000.
EXHIBIT 99.1
GERON ANNOUNCES $9 MILLION IN PRIVATE FINANCING
MENLO PARK, CA - March 10, 2000 - Geron Corporation (Nasdaq: GERN)
announced today that it has sold $9 million in common stock and warrants in
a private placement to a high net worth individual investor. The common
stock and stock underlying the warrants will not be registered for resale
and are subject to a two-year prohibition on sale.
The sale of securities was structured in two tranches. The first tranche
consisted of common stock priced approximately at market and warrants
priced at a premium to market; the second tranche, approximately 30% of the
stock and warrants, was priced at a discount to market.
The funding will be primarily directed to the development of products for
human therapeutic and cosmeceutical applications for treating skin
disorders, including burns, wounds, ulcers, sun damage and other
age-related conditions. This skin program incorporates Geron's three
patented core technology platforms of telomerase, human pluripotent stem
cells and nuclear transfer.
"This investor is a substantial current Geron shareholder," said David L.
Greenwood, Geron's chief financial officer. "We are pleased with his
decision to significantly increase his investment in the company. This
earmarked funding will allow us to accelerate progress in our skin
program."
Geron is a biopharmaceutical company focused on discovering, developing and
commercializing therapeutic and diagnostic products for applications in
oncology, drug discovery and regenerative medicine. Geron's product
development programs are based upon three patented core technologies:
telomerase, human pluripotent stem cells and nuclear transfer.
Contact: Company
David L. Greenwood
Chief Financial Officer
Geron Corporation
650-473-7700
Investor Inquiries
Dennis Schwartz
Burns McClellan
212-213-0006
